Search results

Source:

electronic Medicines Compendium - eMC (Remove filter)

Published by electronic Medicines compendium, 28 July 2020

SPC has been updated to warn co-administration with fostamatinib (FS) may increase FS metabolite R406 exposure resulting in dose-related ADRs such as hepatotoxicity, neutropenia, hypertension, or...

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

electronic Medicines Compendium - eMC (Remove filter)

Published by electronic Medicines compendium, 28 July 2020

SPC has been updated to warn rare cases of anaphylactic reactions have been reported in post-marketing setting & previous warning on Crohn’s disease (CD) has been updated with statement that...

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

electronic Medicines Compendium - eMC (Remove filter)

Published by electronic Medicines compendium, 28 July 2020

SPC has been updated to warn co-administration with fostamatinib (FS) may increase FS metabolite R406 exposure resulting in dose-related ADRs such as hepatotoxicity, neutropenia, hypertension, or...

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

electronic Medicines Compendium - eMC (Remove filter)

Published by electronic Medicines compendium, 27 July 2020

SPC warns cases of hypoglycaemia have been reported when abiraterone acetate plus prednisone/prednisolone was administered to patients with pre-existing diabetes receiving pioglitazone or...

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

electronic Medicines Compendium - eMC (Remove filter)

Published by electronic Medicines compendium, 29 July 2020

SPC now gives option for reconstituted solution to be used within 24 hours when dissolved in bottled water & stored <25°C. It now advises against use in pts with rare hereditary problems of fructose...

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

electronic Medicines Compendium - eMC (Remove filter)

Published by electronic Medicines compendium, 29 July 2020

These new strengths have been added to product range that comprises 1 mg and 2.5mg/ml infusions, licensed for treatment of idiopathic/heritable pulmonary arterial hypertension to improve exercise...

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

electronic Medicines Compendium - eMC (Remove filter)

Published by electronic Medicines compendium, 03 August 2020

This combination of beta-lactamase inhibitor, carbapenem and enzyme inhibitor which blocks renal metabolism of imipenem (cilastatin) is indicated for treatment of aerobic Gram-negative infections...

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

electronic Medicines Compendium - eMC (Remove filter)

Published by electronic Medicines compendium, 03 August 2020

SPCs updated to advise co-treatment with known inducers of uridine 5'-diphosphoglucuronosyltransferase (e.g. rifampicin or phenytoin) is not recommended due to potential risk of decreased efficacy of...

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

electronic Medicines Compendium - eMC (Remove filter)

Published by electronic Medicines compendium, 30 July 2020

Observational study data on the incidence of osteonecrosis of the jaw has been added to section 4.8.

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

electronic Medicines Compendium - eMC (Remove filter)

Published by electronic Medicines compendium, 30 July 2020

This product is licensed for use as a substitution treatment for opioid drug dependence in individuals aged >15 years who have agreed to be treated, within a framework of medical, social and...

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)